NCT07129421View on ClinicalTrials.gov

Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR

NANot yet recruitingINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

October 21, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

March 15, 2027

Conditions
AORTIC VALVE DISEASESAortic Valve Stenosis and/or InsufficiencyAortic Valve RegurgitationAortic Valve Replacement
Interventions
DEVICE

"EMBLOK™ Embolic Protection System (EMBLOK EPS)"

The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.

All Listed Sponsors
collaborator

Yale Cardiovascular Research Group

OTHER

lead

Emblok, Inc.

INDUSTRY

NCT07129421 - Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR | Biotech Hunter | Biotech Hunter